Shares of GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) traded up 8.8% during trading on Wednesday. The company traded as high as $51.35 and last traded at $51.4450. 529,900 shares changed hands during mid-day trading, a decline of 44% from the average session volume of 943,280 shares. The stock had previously closed at $47.29.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on WGS. Wall Street Zen raised GeneDx from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. BTIG Research reissued a "buy" rating and issued a $85.00 price target on shares of GeneDx in a report on Wednesday. Weiss Ratings restated a "sell (d)" rating on shares of GeneDx in a research report on Monday, November 2nd. Zacks Research upgraded GeneDx from a "hold" rating to a "strong-buy" rating in a research report on Monday. Finally, Guggenheim upped their price objective on GeneDx from $74.00 to $83.00 and gave the stock a "buy" rating in a research note on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $90.14.
Get Our Latest Analysis on GeneDx
GeneDx Price Performance
The company has a 50 day moving average of $72.36 and a two-hundred day moving average of $69.72. The firm has a market cap of $1.53 billion, a P/E ratio of -13.54 and a beta of 2.00. The company has a quick ratio of 3.85, a current ratio of 4.16 and a debt-to-equity ratio of 0.60.
GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.07 by $0.21. The firm had revenue of $123.10 million during the quarter, compared to analysts' expectations of $122.93 million. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.98%. During the same period last year, the firm posted ($0.27) earnings per share. Sell-side analysts expect that GeneDx Holdings Corp. will post -0.41 EPS for the current year.
Insider Transactions at GeneDx
In related news, CFO Kevin Feeley sold 3,728 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $363,890.08. Following the completion of the sale, the chief financial officer directly owned 44,945 shares in the company, valued at approximately $4,387,081.45. This trade represents a 7.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the transaction, the chief executive officer owned 115,476 shares in the company, valued at approximately $11,271,612.36. This represents a 8.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 19,206 shares of company stock valued at $1,808,056 over the last 90 days. Corporate insiders own 25.17% of the company's stock.
Hedge Funds Weigh In On GeneDx
A number of hedge funds have recently added to or reduced their stakes in WGS. First Light Asset Management LLC lifted its stake in GeneDx by 222.7% in the second quarter. First Light Asset Management LLC now owns 783,923 shares of the company's stock valued at $53,816,000 after acquiring an additional 540,996 shares during the last quarter. Bank of America Corp DE increased its stake in shares of GeneDx by 77.5% during the 1st quarter. Bank of America Corp DE now owns 234,606 shares of the company's stock worth $15,066,000 after purchasing an additional 102,456 shares during the last quarter. Lazard Asset Management LLC acquired a new position in shares of GeneDx during the 1st quarter worth $2,177,000. Bank of New York Mellon Corp acquired a new position in shares of GeneDx during the 2nd quarter worth $4,258,000. Finally, Assenagon Asset Management S.A. raised its holdings in shares of GeneDx by 108.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 632,413 shares of the company's stock valued at $45,723,000 after purchasing an additional 328,980 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.
About GeneDx
(
Get Free Report)
GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company's testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.